Search clinical trials for: camrelizumab + famitinib

Total 712 results

Peking Union Medical College Hospital

Recruiting

Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer (NITDC)

Colon Cancer | Immunotherapy | Mismatch Repair Deficiency

China
Zhejiang Cancer Hospital

Recruiting

Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer

Bladder Cancer

China
Harbin Medical University

Not yet recruiting

A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis

Lung Metastases | Colorectal Cancer Metastatic | Liver Metastases
AB Science

Completed

Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

Multiple Sclerosis
Shandong Cancer Hospital and Institute

Recruiting

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Neoadjuvant Therapy | Resectable Lung Non-Small Cell Carcinoma | IMMUNOTHERAPY | Biomarkers / Blood

China
West China Hospital

Recruiting

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas

Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Affiliated Hospital of Nantong University
The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province...

Recruiting

A Real World Study of Camrelizumab in the Treatment of Advanced Non-squamous Non-small-cell Lung Cancer

Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma

Disease-free Survival Rate

China
AB Science

Recruiting

Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

Covid19 | Coronavirus Disease 2019 | SARS-CoV2 Infection

France, Russian Federation, South Africa
yue junhan

Recruiting

Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer (FOBECAMS)

Colorectal Cancer

China
Yanqiao Zhang

Withdrawn

A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）

Pancreatic Cancer | Liver Metastasis
Chinese PLA General Hospital

Recruiting

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Hodgkin Lymphoma | Anti-PD-1 Antibody Resistant

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Ruijin Hospital

Not yet recruiting

Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer

Thyroid Cancer
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma

Gastric Cancer

China
Zhang Bi Xiang, MD

Recruiting

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma (CCGLC-003)

Hyperbaric Oxygen Therapy | Combinational Immunotherapy | Hepatocellular Carcinoma Non-Resectable

China
Fudan University

Recruiting

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer

China
The Second Affiliated Hospital of Fujian Medical...

Active, not recruiting

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

Digestive System Diseases | Neoplasms | Neoplasms by Site | Stomach Neoplasms | Digestive System Neoplasms | Stomach Diseases

China
Zhejiang Cancer Hospital
Zhejiang Provincial People's Hospital; Jinhua Municipal Central Hospital; Huizhou... and other collaborators

Not yet recruiting

A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

Esophageal Cancer

China
Eye & ENT Hospital of Fudan University
Chinese Academy of Medical Sciences

Recruiting

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
Beijing Konruns Pharmaceutical Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Completed

Kanitinib in Treating Patients With Advanced Solid Tumors

Solid Tumors

China
AB Science

Terminated

Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

Gastro-Intestinal Stromal Tumour
Hospital of Stomatology, Wuhan University
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma (NEOPBOSCC)

Oral Squamous Cell Carcinoma

China
Wuhan Union Hospital, China

Recruiting

The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study

Hepatocellular Carcinoma

China
Fudan University
Shanghai Shen Kang Hospital Development Center

Recruiting

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Urinary Bladder Neoplasms | Immunotherapy

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer

Esophageal Cancer

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer
Sun Yat-sen University

Active, not recruiting

PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma (DIPPER)

Nasopharyngeal Neoplasms

China
Shanghai Minimally Invasive Surgery Center

Suspended

A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer

Gastric Cancer

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Skin

China
Lei Li

Recruiting

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Cervical Carcinoma | Immunotherapy | Survival Outcomes | Adverse Events | Locally Advanced Cervical Cancer | Chemoradiotherapy | Immune Checkpoint Inhibitor | Anti-programmed Cell Death Receptor 1 | Early Stage Cervical Cancer

China
AB Science

Completed

Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Neoplasia

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
Fudan University

Recruiting

Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract

Malignant Melanoma

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Completed

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Breast Cancer

China
Castle Creek Pharmaceuticals, LLC

Completed

A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers

Healthy

United States
AB Science

Completed

Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

Gastro-intestinal Stromal Tumours

France
Yue Han
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

Unresectable Hepatocellular Carcinoma

China
Third Affiliated Hospital, Sun Yat-Sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Locally Advanced Gastric Cancer

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

Cervical Cancer

China
Fudan University

Recruiting

Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Advanced Malignant Tumors

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Head and Neck Squamous Cell Carcinoma

China
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Advanced Solid Tumor | Advanced Cancer | Lung Cancer, Nonsmall Cell

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial (MAGIC)

Multiple Primary Lung Cancer

China
Wuhan Union Hospital, China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

Rectal Cancer

China
Shanghai Zhongshan Hospital

Enrolling by invitation

Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

Hepatocellular Carcinoma

China
AB Science

Completed

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Relapse Free

Poland, Spain, Bulgaria, France, Germany, Greece, Romania
Peking University Cancer Hospital & Institute

Unknown

Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma (BJCH-MM-0624)

Advanced Mucosal Melanoma

China

3

Subscribe